EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases

International Journal of Oncology

Volumn 31, Issue 3, 2007, Pages 493-499

  Wei, Qichun ^a,b   Chen, Lirong ^a   Sheng, Liming ^a   Nordgren, Hans ^b   Wester, Kenneth ^b   Carlsson, Jörgen ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

c erb B2; Clinical; EGFR; Esophageal carcinoma; HER2; HER3; Metastasis; Overexpression of receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

AGED; ARTICLE; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 38449111136     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.3.493     Document Type: Article

References (42)

1. Tew WP, Kelsen DP and Ilson DH: Targeted therapies for esophageal cancer. Oncologist 10: 590-601, 2005.
2. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK and Fremgen AM: Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 190: 562-572, 2000.
3. Van Lanschot JJ, Aleman BM and Richel DJ: Esophageal carcinoma: surgery, radiotherapy, and chemotherapy. Curr Opin Gastroenterol 18: 490-495, 2002.
4. Crehange G, Bosset M, Fabrice L, Buffet-Miny J, Dumas JL, Mercier M, Puyraveau M, Maingon P and Bosset JF: Tumor volume as outcome determinant in patients treated with chemoradiation for locally advanced esophageal cancer. Am J Clin Oncol 29: 583-587, 2006.
5. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Eng J Med 326: 1593-1598, 1992.
6. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003.
7. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T and Tennvall J: Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66: 107-117, 2003. (Pubitemid 36321806)
8. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
9. Yarden Y and Ullrich A: Growth factor receptor tyrosine kinases. Ann Rev Biochem 57: 443-478, 1988.
10. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
11. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T and Nexo E: The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer 94: 1703-1709, 2006.
12. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N and Volant A: Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 93: 107-115, 2005.
13. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N and Ooi A: EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118: 1173-1180, 2006.
14. Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, Franklin W, Said S and Varella-Garcia M: Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131: 111-119, 2005.
15. Aloia TA, Harpole DH Jr, Reed CE, Allegra C, Moore MB, Herndon JE II and D'Amico TA: Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 72: 859-866, 2001. (Pubitemid 32846247)
16. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E and Forastiere A: Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9: 6461-6468, 2003.
17. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR and Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063, 2000.
18. Hightower M: Erlotinib (OSI-774, Tarceva), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small cell lung cancer. Clin Lung Cancer 4: 336-338, 2003.
19. Goldberg RM: Cetuximab. Nat Rev Drug Discov Suppl: S10-S11, 2005.
20. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA and Bell DW: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12: 4283-4287, 2006.
21. Lam KY, Tin L and Ma L: C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol 24: 431-435, 1998.
22. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A and Fujii H: Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92: 1253-1260, 2005.
23. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, Tsurumaru M and Sasai K: c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57: 1323-1327, 2003.
24. Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G and Bergqvist M: HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 19: 224-231, 2006. (Pubitemid 44027082)
25. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, Korc M and Buchler MW: Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 23: 1010-1018, 1999.
26. Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR and Sauter G: Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20: 120-129, 2007.
27. Barnes DM and Miles DW: Response of metastatic breast cancer to trastuzumab? Lancet 355: 160-161, 2000.
28. Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C and Gullick WJ: Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 7: 1273-1278, 1992.
29. Gullick WJ: c-erbB-4/HER4: friend or foe? J Pathol 200: 279-281, 2003.
30. Wester K, Sjostrom A, De la Torre M, Carlsson J and Malmstrom PU: HER-2-a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 41: 282-288, 2002.
31. Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H and Blomqvist C: HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90: 2344-2348, 2004.
32. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G and van de Vijver M: Current perspectives on HER2 testing: a review of National Testing Guidelines. Mod Pathol 16: 173-182, 2003.
33. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, van Groeningen C and Giaccone G: Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24: 1612-1619, 2006.
34. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S and Nagura H: Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74: 795-804, 1994.
35. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Lauter J, Lessig R, Krishnamurthi K, Ullrich A and Hengstler JG: ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24: 4317-4323, 2006.
36. Leibl S, Bodo K, Gogg-Kammerer M, Hrzenjak A, Petru E, Winter R, Denk H and Moinfar F: Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: an immunohistochemical study. Gynecol Oncol 101: 18-23, 2006. (Pubitemid 43303554)
37. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D and Economopoulos T: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6: 46, 2006.
38. Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, Gebhard S, Beeh KM, Oesch F and Buhl R: c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 92: 474-479, 2001.
39. Damstrup L, Rygaard K, Spang-Thomsen M and Poulsen HS: Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res 52: 3089-3093, 1992.
40. Livasy CA, Reading FC, Moore DT, Boggess JF and Lininger RA: EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 100: 101-106, 2006.
41. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006.
42. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD and Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005. (Pubitemid 41464705)